These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 19655143)

  • 1. Long-term response to deferiprone therapy in Asian Indians.
    Panigrahi I; Marwaha RK; Das RR
    Ann Hematol; 2010 Feb; 89(2):135-40. PubMed ID: 19655143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators.
    al-Refaie FN; Hershko C; Hoffbrand AV; Kosaryan M; Olivieri NF; Tondury P; Wonke B
    Br J Haematol; 1995 Sep; 91(1):224-9. PubMed ID: 7577638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
    Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
    Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients.
    Hoffbrand AV; AL-Refaie F; Davis B; Siritanakatkul N; Jackson BF; Cochrane J; Prescott E; Wonke B
    Blood; 1998 Jan; 91(1):295-300. PubMed ID: 9414297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally active iron chelators in the treatment of iron overload.
    Olivieri NF
    Curr Opin Hematol; 1996 Mar; 3(2):125-30. PubMed ID: 9372062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferiprone-induced agranulocytosis: 20 years of clinical observations.
    Tricta F; Uetrecht J; Galanello R; Connelly J; Rozova A; Spino M; Palmblad J
    Am J Hematol; 2016 Oct; 91(10):1026-31. PubMed ID: 27415835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
    Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.
    Jamuar SS; Lai AH; Tan AM; Chan MY; Tan ES; Ng IS
    J Paediatr Child Health; 2011 Nov; 47(11):812-7. PubMed ID: 21902752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
    Elalfy M; Wali YA; Qari M; Al Damanhouri G; Al-Tonbary Y; Yazman D; Al Hawsawi Z; Karakas Z; Kilinc Y; Yesilipek MA; Badr M; Elsafy U; Salama M; Abdel Rahman Y; Shebl S; Stilman A; Toiber Temin N; Tricta F
    Pediatr Blood Cancer; 2014 May; 61(5):879-84. PubMed ID: 24376176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.
    Botzenhardt S; Sing CW; Wong IC; Chan GC; Wong LY; Felisi M; Rascher W; Ceci A; Neubert A
    Curr Drug Saf; 2016; 11(2):137-44. PubMed ID: 26419768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
    Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
    Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
    Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
    Cermak J; Jonasova A; Vondrakova J; Walterova L; Hochova I; Siskova M; Neuwirtova R
    Hemoglobin; 2011; 35(3):217-27. PubMed ID: 21599434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A trial of deferiprone in transfusion-dependent iron overloaded children.
    Lucas GN; Perera BJ; Fonseka EA; De Silva DD; Fernandopulle M
    Ceylon Med J; 2000 Jun; 45(2):71-4. PubMed ID: 11051705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
    al-Refaie FN; Wonke B; Hoffbrand AV; Wickens DG; Nortey P; Kontoghiorghes GJ
    Blood; 1992 Aug; 80(3):593-9. PubMed ID: 1638018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Iron chelation in 1998].
    de Montalembert M
    Transfus Clin Biol; 1998 Oct; 5(5):353-6. PubMed ID: 9836396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.